ARSPHARMA
ActiveSummary
ARSPHARMA has been active since 2012 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €197,851 and a net result of €28,113. Equity is growing by ~15.7% per year across the filed fiscal years. Its solvency ranks better than 26% of 2028 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
Checked score
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
This company filed its last 7 accounts on average 26 days before the deadline; the sector median for financial year 2024 is 8 days before the deadline, and 33% of the sector filed late.
Checked, nothing found (2)
History
Go further with this company
Is this your company? See how customers and banks see it.
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2025, abbreviated schema
Click a name to add, emphasise or remove a line.Band: the middle half (P25 to P75) of NACE 71, Architectural and engineering activities; technical testing and analysis, each year against the same schema; no band under 30 filings. Dashed line: the median.
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Non-recurring operating income76A | - | - | - | - | €66,116 | - |
| Remuneration, social security and pensions62 | €21,586 | €21,409 | €26,961 | €28,703 | €22,890 | ▼ 20.3% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €9,772 | €9,772 | €9,772 | €10,184 | €11,227 | ▲ 10.2% |
| Other operating charges640/8 | €1,076 | €587 | €1,932 | €6,004 | €2,728 | ▼ 54.6% |
| Gross operating margin9900 | €60,376 | €40,521 | €92,408 | €69,943 | €101,856 | ▲ 45.6% |
| Operating profit (loss)9901 | €27,942 | €8,752 | €53,742 | €25,051 | €65,010 | ▲ 160% |
| Financial income75/76B | €0 | €280 | €434 | €36 | €1 | ▼ 98.3% |
| Recurring financial income75 | €0 | €280 | €434 | €36 | €1 | ▼ 98.3% |
| Financial charges65/66B | €7,860 | €8,929 | €4,711 | €2,459 | €12,487 | ▲ 408% |
| Recurring financial charges65 | €7,860 | €8,929 | €4,711 | €2,459 | €12,487 | ▲ 408% |
| Profit (loss) for the period before taxes9903 | €20,082 | €103 | €49,465 | €22,628 | €52,524 | ▲ 132% |
| Income taxes67/77 | €6,068 | €1,221 | €17,215 | €10,154 | €24,411 | ▲ 140% |
| Profit (loss) for the period9904 | €14,014 | -€1,118 | €32,250 | €12,475 | €28,113 | ▲ 125% |
| Profit (loss) for the period to be appropriated9905 | €14,014 | -€1,118 | €32,250 | €12,475 | €28,113 | ▲ 125% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €872,010 | €775,262 | €847,696 | €703,875 | €839,146 | ▲ 19.2% |
| Fixed assets21/28 | €464,090 | €454,317 | €444,545 | €441,576 | €430,349 | ▼ 2.5% |
| Intangible fixed assets21 | - | - | - | - | €0 | - |
| Tangible fixed assets22/27 | €39,090 | €29,317 | €19,545 | €16,576 | €5,349 | ▼ 67.7% |
| Furniture and vehicles24 | - | - | - | €6,804 | €5,349 | ▼ 21.4% |
| Other tangible fixed assets26 | €39,090 | €29,317 | €19,545 | €9,772 | €0 | ▼ 100% |
| Financial fixed assets28 | €425,000 | €425,000 | €425,000 | €425,000 | €425,000 | = |
| Current assets29/58 | €407,920 | €320,945 | €403,151 | €262,299 | €408,797 | ▲ 55.9% |
| Amounts receivable within one year40/41 | €119,716 | €137,753 | €215,464 | €143,313 | €300,338 | ▲ 110% |
| Trade receivables40 | €94,841 | €127,079 | €201,723 | €128,077 | €286,850 | ▲ 124% |
| Other amounts receivable41 | €24,875 | €10,674 | €13,741 | €15,236 | €13,487 | ▼ 11.5% |
| Cash at bank and in hand54/58 | €288,204 | €153,391 | €187,686 | €118,986 | €108,459 | ▼ 8.8% |
| Deferred charges and accrued income490/1 | - | €29,801 | - | - | - | - |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €872,010 | €775,262 | €847,696 | €703,875 | €839,146 | ▲ 19.2% |
| Equity10/15 | €126,131 | €125,013 | €157,263 | €169,738 | €197,851 | ▲ 16.6% |
| Contributions10/11 | €6,300 | €6,300 | €6,300 | €6,300 | €6,300 | = |
| Outside capital11 | €6,300 | €6,300 | €6,300 | - | - | - |
| Other1109/19 | €6,300 | €6,300 | €6,300 | - | - | - |
| Reserves13 | €119,831 | €118,713 | €150,963 | €163,438 | €191,551 | ▲ 17.2% |
| Non-distributable reserves130/1 | €1,860 | €1,860 | €1,860 | €1,860 | €1,860 | = |
| Reserves not available under the articles1311 | €1,860 | €1,860 | €1,860 | €1,860 | €1,860 | = |
| Distributable reserves133 | €117,971 | €116,853 | €149,103 | €161,578 | €189,691 | ▲ 17.4% |
| Amounts payable17/49 | €745,879 | €650,249 | €690,433 | €534,137 | €641,295 | ▲ 20.1% |
| Amounts payable after more than one year17 | €350,107 | €246,346 | €177,781 | €161,542 | €130,000 | ▼ 19.5% |
| Financial debts170/4 | €350,107 | €246,346 | €177,781 | €161,542 | €130,000 | ▼ 19.5% |
| Amounts payable within one year42/48 | €364,772 | €285,403 | €398,177 | €372,595 | €501,295 | ▲ 34.5% |
| Current portion of amounts payable after more than one year42 | €59,383 | €70,230 | €68,565 | €69,439 | €12,106 | ▼ 82.6% |
| Trade debts44 | €297,960 | €206,893 | €303,522 | €266,459 | €459,241 | ▲ 72.3% |
| Suppliers440/4 | €297,960 | €206,893 | €303,522 | €266,459 | €459,241 | ▲ 72.3% |
| Advances received on contracts in progress46 | - | - | - | €357 | €357 | = |
| Taxes, remuneration and social security45 | €7,429 | €881 | €18,691 | €28,941 | €22,192 | ▼ 23.3% |
| Taxes450/3 | €6,109 | €852 | €17,227 | €27,473 | €19,869 | ▼ 27.7% |
| Remuneration and social security454/9 | €1,320 | €28 | €1,464 | €1,469 | €2,323 | ▲ 58.2% |
| Other amounts payable47/48 | - | €7,400 | €7,400 | €7,400 | €7,400 | = |
| Accrued charges and deferred income492/3 | €31,000 | €118,500 | €114,475 | - | €10,000 | - |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €14,014 | -€1,118 | €32,250 | €12,475 | €28,113 | ▲ 125% |
| + Depreciation and write-downs630 | €9,772 | €9,772 | €9,772 | €10,184 | €11,227 | ▲ 10.2% |
| Operating cash flow (approximation) | €23,786 | €8,654 | €42,023 | €22,659 | €39,341 | ▲ 73.6% |
| Investment in fixed assets (approximation) | - | €0 | €0 | -€7,216 | €0 | ▲ 100% |
| Change in cash | - | -€134,814 | €34,296 | -€68,700 | -€10,527 | ▲ 84.7% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
About the unread acts
We know of 4 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Directors · office · real estate
1 establishment unit
1 parcel
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 11049B0378/00K003 | Flanders | 2,310 m² | 1 · 1,399 m² | 13.7 m |
Linked by address, not proof of ownership
Structure & network
Owners and holdings
2 owners · 1 holdingChain of control
- MDC-INTERIEUR
- ARSPHARMA
Highest known parent: MDC-INTERIEUR. The sources do not say who stands above it.
Owners 2
- MDC-INTERIEURparent100%
- REMEDIAparentSourceaccounts REMEDIA 2025100%
Holdings 1
-
100%
According to the annual accounts to 30-09-2025 of ARSPHARMA and those of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.
Connections & network
No current directors or connected companies found in the register.
Public money · subsidies and aid
Flemish government
2023 to 2025 · 2 entries · 1,344 EUR awarded · 1,344 EUR paid| Year | Entries | awarded | paid |
|---|---|---|---|
| 2025 | 1 | 1,020 EUR | 1,020 EUR |
| 2023 | 1 | 324 EUR | 324 EUR |
Similar companies · same sector, comparable size
Identification & contact
Register as of 27 September 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.